OCT-1 activity and molecular response
| Months after treatment . | Average molecular response at 6-month intervals . | |||
|---|---|---|---|---|
| 12 . | 18 . | 24 . | ||
| OCT-1 activity | ||||
| Low (n=29) | 2.6 | 2.6 | 2.8 | |
| High (n=27) | 3.1 | 3.9 | 3.9 | |
| P value | .032 | .006 | .005 | |
| Low OCT-1 activity | ||||
| Less than 600 mg (n=11) | 2.1 | 2.3 | 2.4 | |
| 600 mg or more (n=18) | 2.8 | 3.2 | 3.4 | |
| P value | .121 | .023 | .005 | |
| High OCT-1 activity | ||||
| Less than 600 mg (n=12) | 2.9 | 3.3 | 3.5 | |
| 600 mg or more (n=15) | 2.9 | 3.9 | 3.9 | |
| P value | .789 | .625 | .449 | |
| Months after treatment . | Average molecular response at 6-month intervals . | |||
|---|---|---|---|---|
| 12 . | 18 . | 24 . | ||
| OCT-1 activity | ||||
| Low (n=29) | 2.6 | 2.6 | 2.8 | |
| High (n=27) | 3.1 | 3.9 | 3.9 | |
| P value | .032 | .006 | .005 | |
| Low OCT-1 activity | ||||
| Less than 600 mg (n=11) | 2.1 | 2.3 | 2.4 | |
| 600 mg or more (n=18) | 2.8 | 3.2 | 3.4 | |
| P value | .121 | .023 | .005 | |
| High OCT-1 activity | ||||
| Less than 600 mg (n=12) | 2.9 | 3.3 | 3.5 | |
| 600 mg or more (n=15) | 2.9 | 3.9 | 3.9 | |
| P value | .789 | .625 | .449 | |
Shown is the molecular response (log reduction in BCR-ABL as measured by real-time quantitative polymerase chain reaction [RQ-PCR]) of patients enrolled in TIDEL at 6-month intervals based on low and high OCT-1 activity, then further on the basis of dose. Data are log reductions except for P values.